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Abstract
Prasugrel and ticagrelor are oral P2Y12 receptor inhibitors indicated by the European Society of Cardiology as the 
preferred antiplatelet therapy in patients with acute coronary syndrome (ACS). Despite the long-term and widespread 
presence of these agents in clinical practice, to date they have never been directly compared in a large, randomised 
clinical trial. ISAR-REACT 5 was the first such study, and it reported the superiority of prasugrel over ticagrelor. However, 
due to the arguable methodology of both the planning and the execution of this study, its results should be interpreted 
with caution, and they should not be considered sufficient to justify any changes to the current treatment strategies for 
patients with ACS.
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Introduction
Dual antiplatelet therapy, consisting of acetylsalicylic acid 
and a P2Y12 receptor inhibitor, is the standard for the tre-
atment of patients with acute coronary syndrome (ACS). 
According to the current guidelines of the European Society 
of Cardiology (ESC) regarding myocardial revascularization, 
the preferred drugs in patients with ACS are prasugrel and 
ticagrelor (class of recommendation I, level of evidence B), 
except for patients treated with thrombolysis and those 
receiving oral anticoagulants, in whom we should use clo-
pidogrel [1]. The use of prasugrel is limited to patients who 
have not previously received a P2Y12 receptor inhibitor and 
are qualified for percutaneous coronary intervention (PCI). 
However, in ACS without persistent ST-segment elevation 
this drug should not be used unless the anatomy of the 
coronary arteries is known. In contrast, ticagrelor can be 
given regardless of previous treatment with a P2Y12 receptor 
inhibitor, and regardless of the treatment strategy adopted. 
Prasugrel is not recommended for the elderly (≥ 75 years) 
or for patients with a low body weight (< 60 kg). A history 
of ischaemic stroke or transient ischaemic attack are 
contraindications to this drug [2, 3].
Clinical efficacy of prasugrel and ticagrelor
The clinical trials that have triggered a change in ESC 
guidelines and have put ticagrelor and prasugrel above 
clopidogrel in the treatment of patients with ACS were, for 
ticagrelor — the PLATO study (Platelet Inhibition and Patient 
Outcomes), and for prasugrel — the TRITON-TIMI 38 trial 
(TRial to assess Improvement in Therapeutic Outcomes by 
optimising platelet inhibitioN with prasugrel — Thrombolysis 
In Myocardial Infarction 38 trial) [4, 5].
Both studies were international, multicentre, randomi-
zed and double-blind, and aimed to compare the efficacy 
of new antiplatelet agents to that of clopidogrel in the pre-
vention of cardiovascular events among patients with ACS. 
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In the PLATO study 18,624 ACS patients were included, 
and 13,608 ACS patients were enrolled in the TRITON-TIMI 
38 study, for whom PCI was planned. In both studies, the 
primary endpoint was a composite of: death from cardiova-
scular causes, myocardial infarction, and stroke. The follow-
-up period in the PLATO study was 12 months with a median 
of 277 days, and in the TRITON-TIMI 38 study was up to 
15 months with a median of 9.5 months. In the PLATO study, 
the primary endpoint occurred in 9.8% of ticagrelor-treated 
patients and in 11.7% of clopidogrel-treated patients [ha-
zard ratio (HR, hazard ratio) 0.84, 95% confidence interval 
(CI, confidence interval) 0.77–0.92, p < 0.001]. Analysing 
endpoints, in the ticagrelor treated patients there was 
a significant reduction in cardiovascular deaths (4.0% vs. 
5.1%, HR 0.79, 95% CI 0.69–0.91, p = 0.001) as well as 
fewer myocardial infarctions (5.8% vs. 6.9%, HR 0.84, 95% 
CI 0.75–0.95, p = 0.005). Surprisingly, it was observed that 
not only the number of cardiovascular deaths but also all-
-cause deaths were reduced in the ticagrelor group (4.5% 
vs. 5.9%, HR 0.78, 95% CI 0.69–0.89, p < 0.001) and 
deaths other than cardiovascular (0.5% vs. 0.8%, HR 0.71, 
95% CI 0.49–1.04, p = 0.08). In TRITON-TIMI 38 trial, the 
primary endpoint occurred in 9.9% of patients treated with 
prasugrel and in 12.1% of patients receiving clopidogrel 
(HR 0.81, 95% CI 0.73–0.90, p < 0.001). The reduction 
in the incidence of the primary endpoint among patients 
treated with prasugrel was mainly due to a reduction in the 
incidence of myocardial infarction (7.3% vs. 9.5%, HR 0.76, 
95% CI 0.67–0.85, p < 0.001). There were no differences 
between the groups in terms of the incidence of cardiovascu-
lar deaths (2.1% vs. 2.4%, HR 0.89, 95% CI 0.70–1.12, p = 
0.31), stroke (1.0% vs. 1.0%, HR 1.02, 95% CI 0.71–1.45, 
p = 0.93), or overall deaths (3.0% vs. 3.2 %, HR 0.95, 95% 
CI 0.78–1.16, p = 0.64).
Safety of prasugrel and ticagrelor
The primary safety endpoint in the PLATO study was major 
bleeding defined by study criteria: it occurred in 11.6% of 
patients in the ticagrelor group and in 11.2% of patients 
in the clopidogrel group (HR 1.04, 95% CI 0.95–1.13, 
p = 0.43). There were also no significant differences be-
tween the study groups in the frequency of major bleeding 
assessed according to the TIMI criteria (7.9% vs. 7.7%, 
HR 1.03, 95% CI 0.93–1.05, p = 0.57) or combined life-
-threatening and fatal bleeds (5.8% vs. 5.8%, HR 1.03, 
95% CI 0.9–1.16, p = 0.70). Analysis of secondary safety 
endpoints showed a significantly higher incidence of major 
bleeding not associated with coronary artery by-pass graf-
ting (CABG) in the ticagrelor group (4.5% vs. 3.8%, HR 1.19, 
95% CI 1.02–1.38, p = 0.03). The primary safety endpoints 
in the TRITON-TIMI 38 study were major non-CABG-related 
bleeding events defined according to the TIMI criteria: these 
occurred in 2.4% of patients treated with prasugrel and in 
1.8% of patients treated with clopidogrel (HR 1.32, 95% CI 
1.03–1.68, p = 0.03). In the prasugrel group as compared 
with the clopidogrel arm, life-threatening bleeding (1.4% 
vs. 0.9%, HR 1.52, 95% CI 1.08–2.13, p = 0.01) and fatal 
bleeding (0.4% vs. 0.1%, HR 4.19, 95% CI 1.58–11.11, 
p = 0.002) were also significantly more commonly ob-
served. Major and minor bleeding assessed according to 
the TIMI criteria also occurred significantly more frequen-
tly in the prasugrel group (5.0% vs. 3.8%, HR 1.31, 95% 
CI 1.11–1.56, p = 0.002), as did CABG-related bleeding 
(13.4% vs. 3.2%, HR 4.73, 95% CI 1.90–11.82, p < 0.001).
Clinical comparison of prasugrel  
and ticagrelor
Despite the long-standing and ever-growing presence of 
prasugrel and ticagrelor in clinical practice, these drugs 
have never been directly compared in a large, randomized 
clinical trial. On the other hand, data from subanalyses 
of clinical trials, large registries or meta-analyses are not 
conclusive as to which of these two drugs is more effective 
in preventing adverse cardiovascular events, as well as in 
comparing the safety of use [6–14].
ISAR-REACT 5 study
The first clinical trial to directly compare the efficacy and 
safety of ticagrelor and prasugrel in patients with ACS was 
the ISAR-REACT 5 study (The Intracoronary Stenting and 
Antithrombotic Regimen: Rapid Early Action for Coronary 
Treatment 5) — a randomized, multicentre, open-label, pha-
se IV study [15]. The study reported superiority of prasugrel 
over ticagrelor in the incidence of a composite endpoint 
consisting of death, myocardial infarction or stroke within 
a year of randomization in patients with ACS. The reduction 
in the incidence of the composite endpoint in patients 
assigned to the prasugrel treatment group was not asso-
ciated with an increased risk of bleeding compared with 
ticagrelor [16]. Based on available data, the cardiological 
community generally expected somewhat different results 
from the ISAR-REACT 5 study. Therefore, it seems necessary 
to investigate and to critically examine the protocol of this 
study, the research methods used, the study population, 
and the conduct of this clinical trial.
The goal of this study was to verify the hypothetical su-
periority of ticagrelor over prasugrel in patients with ACS. In 
fact, it compared different strategies for antiplatelet therapy 
only partially overlapping with the ESC recommendations. 
Patients (n = 4,018) with ST-segment elevation myocardial 
infarction (STEMI) were randomized to the study in the ho-
spital phase of treatment. One of the exclusion criteria was 
previous administration of prasugrel or ticagrelor, in this 
case it prevented the initiation of anti-aggregation therapy 
as soon as possible. In addition, patients with confirmed 
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ACS who were assigned to conservative treatment after 
coronary angiography received a P2Y12 receptor inhibitor 
designated in the randomization process, although the use 
of prasugrel in this group of patients is off-label. Therefore, 
it should be emphasized that the results of this clinical trial 
do not exactly relate to actual clinical practice.
In addition, the study protocol, and how it was organi-
sed, led to potential bias, the degree of which however is 
difficult to assess for several reasons. Both the open nature 
of the study and the fact that it was carried out in only two 
countries (21 centres in Germany and 2 in Italy) could 
have had some, though probably negligible, impact on 
the results. However, the reported percentage of patients 
who followed the recommendations for study medication 
is astonishing, and was 99.1% in the prasugrel group and 
99.6% in the ticagrelor group. For comparison, among the 
entire population of the PLATO study, 82.8% of patients 
declared compliance with medical recommendations 
[4]. The above data seems to clearly indicate an unde-
restimation of the phenomenon of non-adherence to the 
recommended therapy in accordance with the ISAR-REACT 
5 study protocol, all the more so because the follow-up 
visits were mainly without face-to-face contact — in 83% 
of participants it was a telephone conversation, and in 
7% follow-up was based on written correspondence. Only 
10% of study participants had follow-up visits in a hospital 
or outpatient clinic. The 0.9% and 0.4% non-adherence 
rates seem simply unrealistic, especially since ticagrelor 
or prasugrel was prescribed by the attending physician 
after the end of the hospital phase and the patient had to 
purchase the drug without any reimbursement. In addition, 
careful analysis of the patient baseline characteristics 
of both study groups demonstrates a slightly higher risk 
population in the ticagrelor arm as compared with the 
prasugrel arm. However, these differences were not sta-
tistically significant.
The intention-to-treat analysis (i.e. including all patients 
depending on the group to which they were randomly assig-
ned, regardless of the treatment received) is a commonly 
accepted method used in similar clinical trials. However, 
this study model could have seriously distorted the results 
of the ISAR-REACT 5 study because as many as 410 out of 
2,012 (20.4%) and 410 out of 2,006 (20.4%) patients were 
discharged from hospital without the P2Y12 receptor inhibi-
tor assigned in the randomization process in the ticagrelor 
and prasugrel groups respectively. In addition, a further 
243 patients from the ticagrelor group, and 199 from the 
prasugrel group, discontinued the prescribed antiplatelet 
drug after discharge from the hospital. A further 19 and 
18 patients in each group (37 in total, 0.92%) were lost 
to follow-up. For comparison, in the TRITON-TIMI 38 study 
this percentage was 0.12%, and in the PLATO study it was 
0.01% [4, 5]. Consequently, the intention-to-treat analysis 
used in the ISAR-REACT 5 study led to the inclusion in the 
final analysis of as many as 1,299 patients who were not 
treated with the assigned drug [treated with ticagrelor: 
653 of 2,012 participants (32.5%); treated with prasugrel: 
609 out of 2,006 participants (30.4%)].
The primary composite endpoint (death, myocardial 
infarction, or stroke) within a year from randomization 
occurred in 184 of the 2,012 (9.1%) patients assigned 
to the ticagrelor group, and in 137 of the 2,006 (6.8%) 
patients in the group receiving prasugrel (HR 1.36, 95% 
CI 1.09–1.70, p = 0.006). Considering that the analysis of 
4,018 patients included as many as 1,262 people (31.4%) 
who should have been on the assigned drug, but were 
in fact not treated according to the study protocol, and 
that a further 37 were lost from observation, an absolute 
difference in the frequency of the occurrence of a main 
endpoint of 47 events is hardly significant. All the more so 
because, in the analysis of the occurrence of the primary 
endpoint in the period from the hospital discharge to the 
time of discontinuation of therapy or completion of clinical 
observation in patients the hospital discharge on the drug 
assigned during the randomization process, i.e. in patients 
presumed to be on the study drug (on-treatment analysis), 
which included 1,602 participants in the ticagrelor group 
and 1,596 participants in the prasugrel group, there 
were no differences between the study groups (ticagrelor-
-treated: 92 events, treated with prasugrel: 71 events; HR 
1.34, 95% CI 0.98–1.82). It is worth emphasizing that the 
difference in the incidence of the primary endpoint was 
mainly due to differences in the occurrence of myocardial 
infarction (treated with ticagrelor: 96 patients (4.8%); 
treated with prasugrel: 60 patients (3.0%), HR 1.63, 95% 
CI 1.18–2.25), including the relatively frequent type 4a or 
4b myocardial infarction (19 and 20 cases in the ticagrelor 
group, respectively, and 11 cases in the prasugrel group). 
This again raises the question of the true degree of patient 
compliance in the study.
In modified intention-to-treat analysis, the safety-related 
endpoint [severe bleeding according to the BARC (Bleeding 
Academic Research Consortium) criteria, i.e. type 3–5] 
occurred in 95 patients (5.4%) from the ticagrelor group 
and in 80 patients (4.8%) in the prasugrel group (HR 1.12, 
95% CI 0.83–1.51, p = 0.46). The absolute difference 
between the study groups of 15 haemorrhagic events 
is extremely difficult to interpret, given that 233 out of 
2,006 patients (12%) from the prasugrel group, and only 
23 out of 2,012 patients (1%) from the ticagrelor group, 
were excluded from this analysis.
Conclusions
The results of the ISAR-REACT 5 study raise a number of 
questions and must be interpreted with caution [17]. Par-
ticularly incomprehensible are the researchers’ decisions 
to discontinue the study drug in the hospital phase, which 
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in effect led to a comparison of groups in which almost 
one third of patients was not treated with the assigned 
drug. Similarly, the assumption that more than 99% of 
patients purchased and took the prescribed drug without 
actual control of this fact seems at least to be risky. Such 
doubts multiply when comparing the results of this study 
with previous clinical trials in which the study groups were 
many times larger. The incidence of the primary endpoint 
in ticagrelor treated patients in the ISAR-REACT 5 study and 
the PLATO study was similar at 9.3% and 9.8%, respectively. 
However, the comparison of  the results of the ISAR-REACT 
5 study and the TRITON-TIMI 38 study shows surprising and 
difficult-to-explain differences: the incidence of the primary 
endpoint in the prasugrel treated patients being 6.9% and 
9.9%, respectively.
Given the significant limitations of the ISAR-REACT 
5 study, the results obtained should be treated with extre-
me caution and cannot be considered sufficient to alter 
the current treatment strategy. In addition, an in-depth 
reflection on the methodology of how clinical trials are 
conducted is called for.
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Streszczenie
Prasugrel i tikagrelor są doustnymi inhibitorami receptora P2Y12 wskazywanymi w wytycznych Europejskiego Towarzystwa 
Kardiologicznego jako preferowane leczenie przeciwpłytkowe u pacjentów z ostrymi zespołami wieńcowymi (ACS). Mimo 
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ich bezpośrednio w dużym, randomizowanym badaniu klinicznym. Pierwszym takim badaniem była próba kliniczna ISAR-
-REACT 5, w której wykazano wyższość prasugrelu nad tikagrelorem. Tym niemniej, ze względu na wątpliwości odnośnie 
do metodologii planowania i przeprowadzenia tej próby klinicznej, jej wyniki należy interpretować z ostrożnością i nie 
powinno się ich uznawać za wystarczające do wprowadzenia zmian w dotychczasowej strategii leczenia pacjentów z ACS.
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